Skip to main content
. 2019 Feb 21;16(4):637. doi: 10.3390/ijerph16040637

Figure 2.

Figure 2

Survival curves of 437 early stage epithelial ovarian carcinoma women stratified by chemotherapeutic regimens and histologic type with multivariate Cox regression models after adjusting for FIGO stage, tumor grade, and age at diagnosis. (A) Estimated 5-year disease-free survival (DFS) curves. A1: Serous type, A2: Endometrioid type, A3: Clear cell type, A4: Mucinous type. Patients with clear cell histology treated with platinum and paclitaxel (PT) regimens had significantly longer 5-year DFS than those treated with platinum and cyclophosphamide (CP) regimens (91.2% vs. 82.0%, aHR = 0.45, 95% CI = 0.21–0.93, p = 0.043, log-rank test). The 5-year DFS of the other histologic types did not differ with PT or CP regimens. (B) Estimated 5-year overall survival (OS) curves. B1: Serous type, B2: Endometrioid type, B3: Clear cell type, B4: Mucinous. The 5-year OS rate of patients with clear cell histology (93.5% vs. 79.0%, aHR = 0.30, 95% CI = 0.13–0.70, p = 0.005) treated with PT regimens was also higher than those treated with CP regimens. There was no difference in 5-year OS, regardless of treatment with PT or CP regimens, in patients with the serous (86.2% vs. 87.8%, p = 0.825), endometrioid (89.4% vs. 89.7%, p = 0.739), and mucinous (aHR = 0.63, 95% CI = 0.16–2.38, p = 0.520) types (all by log-rank test).